Brivaracetam

Summary

Brivaracetam (CHEMBL607400) is an approved small-molecule anticonvulsant (ATC N03AX23) targeting SV2A; indicated across 9 conditions including epilepsy and visual epilepsy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N03AX23
• Targets: 1 (SV2A)
• Indications: 9 conditions
• Clinical trials: 48
• Chemistry: 212.29 Da · C11H20N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL607400
Name	Brivaracetam
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	9837243
ChEBI	CHEBI:133013
ATC	N03AX23
Molecular formula	C11H20N2O2
Molecular weight	212.29
InChIKey	MSYKRHVOOPPJKU-BDAKNGLRSA-N

SMILES: CCC[C@@H]1CC(=O)N(C1)[C@@H](CC)C(=O)N

IUPAC name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide

ChEBI definition: A non-proteinogenic amino acid derivative that is butanamide in which the pro-S hydrogen at position 2 is replaced by a (4R)-2-oxo-4-propylpyrrolidin-1-yl. Used for treatment of partial onset seizures related to epilepsy.

Pharmacological roles (ChEBI): anticonvulsant.

Also known as: Brivaracetam, Briviact, Briviact (in italy: nubriveo), Briviact (in italy: nubriveo), UCB 34714, UCB-34714, UCB34714, BRIVARACETAM, BRIVIACT, BRIVIACT (IN ITALY: NUBRIVEO), BRIVIACT (IN ITALY: NUBRIVEO)

Patent coverage: 884 distinct patent families (2,743 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SV2A	synaptic vesicle glycoprotein 2A	Inhibition	7	5.6%	Q7L0J3

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): SV2A.

Top Reactome pathways

9 total, by targets touching each:

Pathway	Targets	Genes
Disease	1	SV2A
Neurotoxicity of clostridium toxins	1	SV2A
Toxicity of botulinum toxin type D (botD)	1	SV2A
Toxicity of botulinum toxin type A (botA)	1	SV2A
Toxicity of botulinum toxin type F (botF)	1	SV2A
Toxicity of botulinum toxin type E (botE)	1	SV2A
Uptake and actions of bacterial toxins	1	SV2A
Infectious disease	1	SV2A
Bacterial Infection Pathways	1	SV2A

Dominant GO biological processes

GO term	Targets
intracellular calcium ion homeostasis	1
synaptic vesicle priming	1
neurotransmitter transport	1
chemical synaptic transmission	1
transmembrane transport	1

Indications & clinical

Indications

9 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
epilepsy	4	MONDO:0005027	EFO:0000474
visual epilepsy	4	MONDO:0001386	HP:0001250
Unverricht-Lundborg syndrome	3	MONDO:0009698	Orphanet:308
spinal cord injury	1	MONDO:0043797	EFO:1001919
brain neoplasm	0	MONDO:0021211	EFO:0003833

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 48.

Phase distribution

Phase	Trials
PHASE3	24
PHASE2	8
PHASE1	8
Not specified	5
PHASE1/PHASE2	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04666610	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
NCT04715646	PHASE3	RECRUITING	A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
NCT06315322	PHASE3	RECRUITING	A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
NCT00150800	PHASE3	COMPLETED	This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment
NCT00357669	PHASE3	COMPLETED	Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults
NCT00464269	PHASE3	COMPLETED	Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures
NCT00490035	PHASE3	COMPLETED	Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures
NCT00504881	PHASE3	COMPLETED	Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy
NCT00698581	PHASE3	TERMINATED	A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
NCT00699283	PHASE3	TERMINATED	A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
NCT00761774	PHASE3	COMPLETED	An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
NCT01261325	PHASE3	COMPLETED	Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures
NCT01339559	PHASE3	COMPLETED	Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy
NCT01364597	PHASE3	COMPLETED	Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy
NCT01405508	PHASE3	COMPLETED	Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy
NCT01653262	PHASE3	COMPLETED	Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
NCT01728077	PHASE3	COMPLETED	Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy
NCT03083665	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
NCT03250377	PHASE3	COMPLETED	A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
NCT03325439	PHASE3	TERMINATED	A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures
NCT03685630	PHASE3	COMPLETED	A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
NCT05109234	PHASE3	COMPLETED	A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
NCT05639946	PHASE3	COMPLETED	Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
NCT07563634	PHASE3	COMPLETED	Long-term Safety and Efficacy of Adjunctive Brivaracetam in Chinese Patients With Uncontrolled Focal Epilepsy
NCT05899764	PHASE1/PHASE2	NOT_YET_RECRUITING	Epileptic Hippocampus in Alzheimer’s Disease
NCT00160667	PHASE2	COMPLETED	A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)
NCT00175825	PHASE2	COMPLETED	A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
NCT00175929	PHASE2	COMPLETED	A Study of Brivaracetam in Subjects With Partial Onset Seizures
NCT00401648	PHASE2	COMPLETED	Effect of Brivaracetam in Photosensitive Epileptic Subjects
NCT00422422	PHASE2	COMPLETED	Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.
NCT02088957	PHASE2	TERMINATED	Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures
NCT03021018	PHASE2	COMPLETED	A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting
NCT03405714	PHASE2	COMPLETED	A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy
NCT04379011	PHASE1/PHASE2	COMPLETED	Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury
NCT00426673	PHASE1	COMPLETED	An Open-Label Interaction Study to Look at the Effects of Brivaracetam on Phenytoin When Taken Together in 15 Adult Patients With Epilepsy.
NCT00736931	PHASE1	COMPLETED	Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam
NCT01710670	PHASE1	COMPLETED	A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects
NCT02602860	PHASE1	COMPLETED	A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers
NCT03695094	PHASE1	COMPLETED	A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil
NCT04882540	PHASE1	COMPLETED	A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).